Clinical hold placed on Solid Biosciences' study

The Food and Drug Administration placed a clinical hold on Solid Biosciences Inc.'s (Nasdaq: SLDB) Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy. The stock price crashed $16.99 to close at $9.32.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.